Now Playing
CLARITY Aftermath: XRP at $1.32–$1.41, ETF Plateau & Goldman Warning
Audio is available on Spreaker — see link below.
The CLARITY Act's 49-50 collapse removed XRP's biggest institutional catalyst of the session — now price is holding on Bitcoin's momentum alone. Today's briefing breaks down the technical floor, ETF inflow slowdown, Coinbase's equity perpetuals filing, and what Goldman's profit warning means for crypto.
Audio is available on Spreaker — see link below.
The Senate just killed the clearest path to crypto regulatory clarity in years. The CLARITY Act cloture vote failed forty-nine to fifty, and for XRP holders, that's not a procedural footnote.
XRP is trading in the one-dollar-thirty-two to one-dollar-forty-one range. The recent green candles look encouraging on a chart, but the signal here is more cautious.
Spot XRP ETFs launched in September twenty-twenty-five near the three-dollar-eight range. Inflows have cooled since.
Away from XRP's immediate legislative setback, the broader institutional infrastructure kept moving. Coinbase Derivatives filed with the CFTC for approval to offer cash-settled perpetual futures on individual stocks and ETFs.
21Shares updated its S-1/A filing for an Injective ETF, proposing to stake between forty and sixty percent of INJ holdings against the FTSE Injective Index, with BNY Mellon as administrator and a Nasdaq listing under the ticker TINJ. In the same window, Injective integrated with Phantom wallet, giving INJ holders direct access across the Solana ecosystem for holding, trading, borrowing, and exchanging.
One macro signal worth tracking: Goldman Sachs flagged slowing corporate profit growth as a vulnerability for equity valuations. The call isn't collapse, it's deceleration.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.